Asset Details
Do you wish to reserve the book?
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Do you wish to request the book?
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
2007
Overview
In this 24-month clinical trial, torcetrapib, a cholesteryl ester transfer protein inhibitor, failed to cause regression of coronary atherosclerosis, as seen on intravascular ultrasonography, even though levels of high-density lipoprotein cholesterol were markedly elevated. The drug was also associated with an elevation in blood pressure, and the entire torcetrapib research program has been suspended.
Torcetrapib, a cholesteryl ester transfer protein inhibitor, failed to cause regression of coronary atherosclerosis, even though levels of high-density lipoprotein cholesterol were markedly elevated.
Epidemiologic studies demonstrate an inverse relationship between levels of high-density lipoprotein (HDL) cholesterol and the incidence of cardiovascular disease.
1
Limited clinical trials have suggested that an increase in HDL cholesterol levels may reduce the progression of coronary atherosclerosis and decrease cardiovascular morbidity.
2
,
3
Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl ester from HDL cholesterol to low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) cholesterol. Recently, the administration of the CETP inhibitor torcetrapib has been shown to increase HDL cholesterol levels by more than 50%.
4
However, the effectiveness of CETP inhibition as a strategy for antiatherosclerotic therapy has . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - therapeutic use
/ Atherosclerosis (general aspects, experimental research)
/ Biological and medical sciences
/ Blood Pressure - drug effects
/ Cardiovascular Diseases - chemically induced
/ Cholesterol Ester Transfer Proteins - adverse effects
/ Cholesterol Ester Transfer Proteins - antagonists & inhibitors
/ Cholesterol, HDL - metabolism
/ Coronary Artery Disease - diagnostic imaging
/ Coronary Artery Disease - drug therapy
/ Coronary Artery Disease - pathology
/ Female
/ Heptanoic Acids - therapeutic use
/ Humans
/ Male
/ Quinolines - adverse effects
